PMID- 37572082
OWN - NLM
STAT- MEDLINE
DCOM- 20240509
LR  - 20240509
IS  - 1522-2586 (Electronic)
IS  - 1053-1807 (Linking)
VI  - 59
IP  - 6
DP  - 2024 Jun
TI  - Molecular MR Imaging of Prostate Cancer by Specified Iron Oxide Nanoparticles 
      With PSMA-11 Peptides: A Preclinical Study.
PG  - 2204-2214
LID - 10.1002/jmri.28949 [doi]
AB  - BACKGROUND: Prostate-specific membrane antigen (PSMA) can provide a prostate 
      cancer (PCa) detection approach in positron emission tomography (PET) using Food 
      and Drug Administration (FDA)-approved PSMA-11 peptide. There are some studies 
      evaluated magnetic-nanoprobes for PSMA detection by MRI, using non-FDA-approved 
      ligands including antibodies or peptides, which are not as specific as PSMA-11. 
      PURPOSE: To assess targeted iron oxide nanoparticles (IONPs) by PSMA-11 peptides 
      as a potential specific nano-molecular probes to investigate a PSMA(+) 
      PCa-xenograft model by MRI. STUDY TYPE: Prospective. ANIMAL MODEL: Twenty male 
      C57BL6 nude mice induced subcutaneously PSMA(+) LNCaP cell line tumor. FIELD 
      STRENGTH/SEQUENCE: 1.5 T, T(2)-W Fast Spin echo and T(2)*-W Gradient echo. 
      ASSESSMENT: Coated IONPs with Carboxymethylated-dextran (DNPs) and with bovine 
      serum albumin (BNPs), as well as, targeted DNPs with PSMA-11-HYNIC peptide 
      (TDNPs) and targeted BNPs with PSMA-11-HBED peptide (TBNPs) were injected 
      intravenously with dose 2.8 mg Fe/kg. Coronal T(2)-W and the T(2)*-W images were 
      obtained before and 4 hours and 6 hours post-injection. Signal intensity (SI) and 
      relative signal enhancement (RSE) were computed in two- and three-dimensional 
      analyses. Histological analysis of tumors was evaluated, and the Fe distribution 
      within the body based on atomic absorption spectroscopy was calculated. 
      STATISTICAL TESTS: One-way ANOVA followed by Tukey's multiple comparison test, 
      Paired-samples T-test, P < 0.05 was considered significant. RESULTS: A reduction 
      in T(2)-W SI was achieved as 22 +/- 7%, 59 +/- 3%, 65 +/- 5%, and 78 +/- 3% respectively 
      for BNPs, TBNPs, DNPs, and TDNPs 6 hours post-injection. The most difference 
      between targeted and non-targeted groups was observed at 6 hours for 
      PSMA-11-HBED, and at 4 hours for PSMA-11-HYNIC. RSE indicated 88.6 +/- 3.1% and 
      80.7 +/- 3.2% enhanced contrast between tumor and muscle region for TBNPs and TDNPs 
      on T(2)*-W images. CONCLUSIONS: Both TBNPs and TDNPs are promising novel 
      nano-molecular probes for PSMA(+) PCa tumor detection. The injection dose of 
      non-targeted IONPs can be reduced by using targeted nanoprobes three times for 
      BNPs and two times for DNPs. EVIDENCE LEVEL: 1 TECHNICAL EFFICACY: Stage 1.
CI  - (c) 2023 International Society for Magnetic Resonance in Medicine.
FAU - Ghorbani, Farzaneh
AU  - Ghorbani F
AD  - Department of Medical Physics and Radiology, Faculty of Medicine, Gonabad 
      University of Medical Sciences, Gonabad, Iran.
FAU - Aminzadeh, Behzad
AU  - Aminzadeh B
AD  - Department of Radiology, Faculty of Medicine, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
FAU - Borji, Nahid
AU  - Borji N
AD  - Ghaem Educational, Research and Treatment Center, Mashhad, Iran.
FAU - Soudmand, Samaneh
AU  - Soudmand S
AD  - Medical Physics Research Center, Mashhad University of Medical Sciences, Mashhad, 
      Iran.
FAU - Montazerabadi, Alireza
AU  - Montazerabadi A
AUID- ORCID: 0000-0001-6756-0318
AD  - Medical Physics Research Center, Mashhad University of Medical Sciences, Mashhad, 
      Iran.
LA  - eng
GR  - 99023254/Iran National Science Foundation/
GR  - 990661/Mashhad University of Medical Sciences (MUMS)/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230812
PL  - United States
TA  - J Magn Reson Imaging
JT  - Journal of magnetic resonance imaging : JMRI
JID - 9105850
RN  - EC 3.4.17.21 (Glutamate Carboxypeptidase II)
RN  - 0 (Antigens, Surface)
RN  - 0 (Peptides)
RN  - EC 3.4.17.21 (FOLH1 protein, human)
RN  - 0 (Contrast Media)
RN  - 1K09F3G675 (ferric oxide)
RN  - 0 (PSMA-11)
RN  - 0 (Ferric Compounds)
RN  - 0 (Gallium Radioisotopes)
SB  - IM
MH  - Male
MH  - *Prostatic Neoplasms/diagnostic imaging
MH  - Animals
MH  - Mice
MH  - *Magnetic Resonance Imaging/methods
MH  - Cell Line, Tumor
MH  - *Mice, Nude
MH  - Humans
MH  - Mice, Inbred C57BL
MH  - Magnetic Iron Oxide Nanoparticles/chemistry
MH  - Glutamate Carboxypeptidase II/metabolism
MH  - Antigens, Surface
MH  - Peptides/chemistry
MH  - Molecular Imaging/methods
MH  - Contrast Media/chemistry
MH  - Ferric Compounds
MH  - Gallium Radioisotopes
OTO - NOTNLM
OT  - PSMA
OT  - iron oxide nanoparticles (IONPs)
OT  - magnetic resonance imaging
OT  - molecular imaging
OT  - prostate cancer
EDAT- 2023/08/13 00:43
MHDA- 2024/05/10 04:24
CRDT- 2023/08/12 09:33
PHST- 2023/07/30 00:00 [revised]
PHST- 2023/05/18 00:00 [received]
PHST- 2023/07/31 00:00 [accepted]
PHST- 2024/05/10 04:24 [medline]
PHST- 2023/08/13 00:43 [pubmed]
PHST- 2023/08/12 09:33 [entrez]
AID - 10.1002/jmri.28949 [doi]
PST - ppublish
SO  - J Magn Reson Imaging. 2024 Jun;59(6):2204-2214. doi: 10.1002/jmri.28949. Epub 
      2023 Aug 12.